Fig. 12.

Effect of CM764 treatment across cell types of different tissues. Human SK-N-SH neuroblastoma, HEK293T human embryonic kidney cells, and MG-63 human osteosarcoma cells were treated with the indicated dose of CM764 for 24 hours. MTT assay was then carried out as described in Materials and Methods. CM764 treatment induced an increase in reduction of MTT reagent in all three cell types examined. These data indicate that the effect of CM764 observed in the neuroblastoma is not a cell line–specific effect but is consistent across multiple cell types, both cancerous and noncancerous. Results are shown as an average percent change in MTT reduction ± S.D. compared with an untreated control in each cell line for at least three independent experiments, with each experiment performed with five replicates per condition.